Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02917473
Other study ID # INCA14/LM-FADEMELA
Secondary ID 2016-A00186-45
Status Completed
Phase N/A
First received
Last updated
Start date December 13, 2017
Est. completion date July 10, 2019

Study information

Verified date July 2019
Source University Hospital, Tours
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

First-degree relatives of patients with melanoma have a greater risk of developing melanoma. Patients are advised orally to inform their first-degree relatives that they should protect their skin from UV radiation and ask for a skin examination from a general practitioner or dermatologist. The study will evaluate the effectiveness of a written sheet in addition to the usual oral counselling to increase acceptance of skin examination by the first-degree relatives. If effective, written counselling provided to the patient for relatives should be recommended and generalized.


Description:

Melanoma (MM) is a common cancer affecting 11,000 new cases per year in France and the incidence has tripled in 30 years. It now includes young people, and is responsible for 1600 deaths /year in France. Greater tumor thickness and delayed diagnosis are associated with higher mortality. Prevention and early detection on a large scale in the general population are effective but expensive. First-degree relatives have a greater risk of developing MM. A study carried out in the USA found that a biennial consultation is justified and cost-effective in first-degree relatives of MM patients. The best way to deliver the message of sun protection and screening by a dermatologist, and the reality of behavioural changes induced by counseling and the psychological determinants of adherence to medical skin examination are not fully understood. A pilot study performed in our center suggested the value of a short written advice provided for participants to give to their relatives to promote sun protection and medical skin examination. The participants reported a significant increase in interest in medical skin examination by their relatives (p=0.006), but the investigators do not know whether the relatives really consulted for examination. The aim of the multicenter cluster-randomized study is to demonstrate that a higher ratio of relatives will in fact consult their GP or dermatologist for skin examination in the centers randomized to the intervention arm, i.e advice leaflet and usual oral counselling, compared to the centers randomized in the control arm, i.e. usual oral counselling. Participants and their relatives in the intervention group will be asked to undergo psychological tests to identify potential barriers to skin examination and sun protection. If effective, the investigators expect to improve the written information and to generalize its distribution at national level.


Recruitment information / eligibility

Status Completed
Enrollment 420
Est. completion date July 10, 2019
Est. primary completion date April 26, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: For Patients: - Personal history of Stage 0 through IIB melanoma - At maximum of 12 weeks after surgical treatment of Stage 0 through IIA melanoma - Have at least one first-degree relative - Speaking and reading French - Affiliated to the French Health Insurance system - Signed non-opposition form at the 1 year consultation For 1st degree relatives: - To be 1st degree related to a patient with melanoma - Speaking and reading French - 1st degree relatives informed by patients and agreeing to fill out the psychological questionnaires and to the use of their personal data by the investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
In-person counseling
In-person counseling Sun protection
Written advice
Written advice
Medical skin screening
Medical skin screening

Locations

Country Name City State
France CHU - ANGERS , Service de Dermatologie Angers
France CHRU BREST Hôpital du Morvan, Institut de Cancérologie et d'Hématologie Brest
France GH La Rochelle Ré Aunis-Service de Dermatologie La Rochelle
France Ch Le Mans Le Mans
France CHU NANTES, Service de Dermatologie Nantes
France CHU-Poitiers _LA MILETRIE POLE MEDIPOOL-DERMATO-ALLERGOLOGIE Poitiers
France Centre Eugène Marquis -Service d'Oncologie médicale Rennes
France CHU -RENNES -Service de Dermatologie-CHU Pontchaillou Rennes
France University Hospital of Tours, Service de Dermatologie Tours

Sponsors (4)

Lead Sponsor Collaborator
University Hospital, Tours Institut d'Enseignement à Distance,University Paris - 8, Institut national de la santé et de la recherche médicale, CIC 1415, TOURS, Institut national de la santé et de la recherche médicale, U930,TOURS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Consulting general practitioner or dermatologist The number of relatives who will have consulted a dermatologist or a general practitioner to perform whole body skin examination 1 year
Secondary Self-skin examination reported by the relatives The number of relatives who declare to have performed Self-skin examination. 1 year
Secondary Sun protection behaviors reported by the relatives Sun protection behaviours reported by the relatives and assessed by a questionnaire 1 year
Secondary Barriers to skin examination identified from psychological questionnaires in patients and their relatives Psychological barriers of patients and their relatives to skin examination evaluated with several questionnaires and scales. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study